CD38 and Regulation of the Immune Response Cells in Cancer

Figure 3

Dara mechanism of action. Dara exerts anticancer activity via Fc-dependent mechanism and immunomodulatory effects. Once bound to CD38 over cancer cells, Fc fragment of Dara allows engagement with Fc Receptors expressing effector cells, i.e., NK cells, T cells, neutrophils, and macrophages, leading to lysis (ADCC) or phagocytosis (ADCP) of the cancer cell. Engagement of Dara’s Fc with C1q outcomes activation of compliment cascade and assembly of MAC complex over cancer cells and lysis (CDC). Dara´s binding mask CD38 ectoenzymatic activity reduces adenosine production and causes eliminations of immune suppressive cell types (i.e.,Tregs, Bregs, MDSCs) that promotes T cell proliferation and effector functions (the figure is reproduced from the original figure published by Overdijk et al. [84] and distributed under the Creative Commons Attribution License).